10 completed, 7 active not recruiting, 7 recruiting, 1 not yet recruiting. 14 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 5, Recruiting 4, Completed 3, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Fundación GECP: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) Biological: Fecal Microbiota Transplantation, Durvalumab, Paclitaxel - Non Small Cell Lung Cancer, Respiratory Tract Neoplasm | Phase 2 | Not yet recruiting | Fundación GECP | 68 | 2026-09-15 | 2026-05-05 |
| Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients Tarlatamab - Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung | Phase 2 | Recruiting | Fundación GECP | 37 | 2026-05-20 | 2026-07-08 |
| PALACE: Cemiplimab Trial According to ctDNA Levels Cemiplimab, Carboplatin, Paclitaxel - Non Small Cell Lung Cancer Metastatic, Lung Diseases | Phase 2 | Recruiting | Fundación GECP | 63 | 2025-07-29 | 2025-11-19 |
| Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) Atezolizumab, Paclitaxel, Carboplatin - Non Small Cell Lung Cancer, Stage IIIA Lung Cancer | Phase 2 | Recruiting | Fundación GECP | 97 | 2025-07-08 | 2025-11-19 |
| Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. Zimberelimab, Sacituzumab govitecan, Cisplatin - Lung Diseases, Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | Fundación GECP | 129 | 2025-02-04 | 2026-05-18 |
| Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients Durvalumab - Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation | Recruiting | Fundación GECP | 50 | 2024-10-03 | 2026-01-28 | |
| Characteristics of Sexual Dysfunction in Patients With Lung Cancer Systemic oncological treatment - Lung Cancer, Sexual Dysfunction | Completed | Fundación GECP | 553 | 2023-07-13 | 2026-02-06 | |
| DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors Carboplatin, Paclitaxel, Nivolumab - NSCLC, Pancoast Tumor | Phase 2 | Active not recruiting | Fundación GECP | 22 | 2023-05-12 | 2026-05-05 |
| Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer Lenvatinib, Pembrolizumab, Etoposide - Small Cell Lung Cancer Extensive Stage | Phase 2 | Active not recruiting | Fundación GECP | 46 | 2022-11-07 | 2026-04-30 |
| Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment | Active not recruiting | Fundación GECP | 100 | 2022-06-17 | 2025-11-19 | |
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy Sotorasib - Non-small Cell Lung Cancer Stage III, KRAS P.G12C | Phase 2 | Recruiting | Fundación GECP | 19 | 2022-03-21 | 2026-04-30 |
| Pathological Response After Neoadjuvant Treatment on NSCLC Cisplatin, Carboplatin - Stage IIIA Non-small Cell Lung Cancer | Recruiting | Fundación GECP | 150 | 2021-12-13 | 2026-02-06 | |
| Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment Lorlatinib - Metastatic Non Small Cell Lung Cancer | Completed | Fundación GECP | 118 | 2021-12-09 | 2023-03-30 | |
| Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Ipilimumab, Nivolumab, Carboplatin - Non Small Cell Lung Cancer, Brain Metastases, Adult | Phase 2 | Active not recruiting | Fundación GECP | 71 | 2021-11-18 | 2026-05-05 |
| Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma Bintrafusp alfa - Mesothelioma; Lung | Phase 2 | Completed | Fundación GECP | 47 | 2021-09-20 | 2025-12-23 |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Carboplatin, Placlitaxel, Atezolizumab - Lung Diseases, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Fundación GECP | 38 | 2021-06-16 | 2026-07-22 |
| Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients COVID-19 vaccine - Lung Cancer, Covid19 | Completed | Fundación GECP | 794 | 2021-05-06 | 2022-07-29 | |
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy Carboplatin, Paclitaxel, Nivolumab - Non-Small Cell Lung Cancer, Adjuvant Chemotherapy | Phase 3 | Active not recruiting | Fundación GECP | 210 | 2021-01-13 | 2026-05-05 |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients Atezolizumab, Bevacizumab, Carboplatin - Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Terminated | Fundación GECP | 4 | 2020-12-02 | 2025-04-02 |
| Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. Durvalumab - Small Cell Lung Cancer (SCLC) | Completed | Fundación GECP | 245 | 2020-05-21 | 2022-06-07 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (19) · Lung Neoplasms (12) · Lung Diseases (7) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (5) · Carcinoma, Bronchogenic (3) · COVID-19 (2) · Small Cell Lung Carcinoma (2) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Coronavirus Infections (1) · Mesothelioma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Pancoast Syndrome (1)
Carboplatin (12) · Paclitaxel (8) · Nivolumab (4) · atezolizumab (4) · durvalumab (4) · Cisplatin (3) · Pemetrexed (2) · Bevacizumab (1) · COVID-19 Vaccines (1) · Drug Therapy (1) · Etoposide (1) · Ipilimumab (1) · Radiotherapy (1) · bintrafusp alfa protein, human (1) · brigatinib (1)
Spain (26) · Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Colombia (1) · France (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Peru (1)
Mariano Provencio, MD (19) · Ernest Nadal, MD (2) · Antonio Calles, MD (1) · Aylen Vanessa Ospina Serrano, MD (1) · Glenwood Goss (1) · Pilar Garrido, MD (1)
PMID 33676426, PMID 35242627, PMID 36520426, PMID 37379158, PMID 37639820, PMID 37917247, PMID 41529222, PMID 41805895
2018 (2), 2019 (1), 2025 (1)